Dementia with Lewy bodies: pathophysiological and therapeutic considerations
DOI:
https://doi.org/10.36557/2674-8169.2024v6n3p2852-2861Keywords:
dementia with Lewy bodies, pathogenesis, treatment, pathophysiologyAbstract
Introduction: Dementia with Lewy bodies (DLB) is a neurodegenerative condition characterized by the presence of Lewy bodies, intracellular aggregates composed mainly of alpha-synuclein. Clinically, DLB is manifested by cognitive symptoms, such as cognitive fluctuations, impaired attention and memory, as well as neuropsychiatric symptoms and parkinsonian symptoms, such as muscle rigidity and tremors. Objective: To evaluate the pathophysiology, pathogenesis and management of dementia with Lewy bodies. Methodology: This is a bibliographic review that included original articles and systematic reviews in English and Portuguese, which addressed the pathogenic, pathophysiological and treatment implications of DLB, published between 2012 and 2024, selected from the PubMed, Scopus and SciELO databases. After careful selection, 15 articles were chosen to compose this bibliographic review. Results: DCL has genetic aspects, including the SNCA, GBA and APOE genes, which play an important role in this process. Furthermore, there are significant immunological implications in DLB, with an increase in CD3+ and CD4+ T cells in some regions of the brain. The treatment of MCI is challenging, focusing on symptom management, with an emphasis on cholinesterase inhibitors for cognitive and neuropsychiatric symptoms. Considerations: DLB is characterized by a complex pathophysiology, marked by genetic aspects and immunopathogenic components relevant to the course of the disease. Clinical management of DLB mainly aims to control symptoms, especially cognitive, neuropsychiatric and sleep-related symptoms. Such therapeutic interventions are crucial to improving patients' comfort and quality of life.
Downloads
References
Amin, J., Gee, C., Stowell, K., Coulthard, D., & Boche, D. (2023). T Lymphocytes and Their Potential Role in Dementia with Lewy Bodies. Cells, 12(18), 2283. https://doi.org/10.3390/cells12182283
Amin, J., Holmes, C., Dorey, R. B., Tommasino, E., Casal, Y. R., Williams, D. M., Dupuy, C., Nicoll, J. A. R., & Boche, D. (2020). Neuroinflammation in dementia with Lewy bodies: A human post-mortem study. Translational Psychiatry, 10, 267. https://doi.org/10.1038/s41398-020-00954-8
Chan, P. C., Lee, H. H., Hong, C. T., Hu, C. J., & Wu, D. (2018). REM sleep behavior disorder (RBD) in dementia with Lewy bodies (DLB). Behavioral Neurology, 2018, 1–10.
Funahashi, Y., Yoshino, Y., Yamazaki, K., Mori, Y., Mori, T., Ozaki, Y., et al. (2017). DNA methylation alterations in intron 1 of SNCA in patients with Lewy body dementia. Clinical Psychiatry and Neuroscience, 71, 28–35.
Gomperts, S. N. (2016). Lewy Body Dementias: Dementia with Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneapolis, Minn.), 22(2 Dementia), 435– 463. https://doi.org/10.1212/CON.0000000000000309
Guerreiro, R., Ross, O. A., Kun-Rodrigues, C., Hernandez, D. G., Orme, T., Eicher, J. D., et al. (2018). Investigating the genetic architecture of dementia with Lewy bodies: A twostage genome-wide association study. Lancet Neurology, 17, 64–74.
Kouli, A., Camacho, M., Allinson, K., & Williams-Gray, C. H. (2020). Neuroinflammation and protein pathology in Parkinson's disease dementia. Acta Neuropathologica Communications, 8, 211. https://doi.org/10.1186/s40478-020-01083-5.
Lapid, M. I., Kuntz, K. M., Mason, S. S., & Kremers, W. K. (2017). Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with Lewy body dementia: A pilot study. Dementia and Geriatric Cognitive Disorders, 43(5–6), 269–280. Lee, G., Cummings, J., Decourt, B., Leverenz, J. B., & Sabbagh, M. N. (2019). Clinical drug development for dementia with Lewy bodies: Past and present. Expert Opinion on Investigational
Drugs, https://doi.org/10.1080/13543784.2019.1681398.
Matsunaga, S., Kishi, T., Yasue, I., et al. (2015). Cholinesterase inhibitors for Lewy body disorders: A meta-analysis. International Journal of Neuropsychopharmacology, 19, 1– 15.
McKeith, I. G., Boeve, B. F., Dickson, D. W., et al. (2017). Diagnosis and treatment of dementia with Lewy bodies: Fourth report of the DLB Consortium. Neurology, 89, 88– 100.
Mori, E., Ikeda, M., Kosaka, K., & the Donepezil-DLB Study Investigators. (2012). Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Annals of Neurology, 72(1), 41–52.
Noufi P, Khoury R, Jeyakumar S, et al. Use of cholinesterase inhibitors in non-Alzheimer’s dementias. Drugs Aging. 2019;36(8):719–731.
Phan, S., Osae, S., Morgan, J., et al. (2019). Neuropsychiatric symptoms in dementia: Considerations for pharmacotherapy in the United States. Drugs in R&D, 19, 93–115.
Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015). Lewy body dementias. Lancet, 386(10004), 1683–1697. https://doi.org/10.1016/S0140-6736(15)00462-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Paulo Vytor Cardoso Nobre, Rodrigo de Albuquerque Cavalcante Barreto, Victor Lorenzzo Wanderley de Jesus Correia, Tulio Lustosa de Oliveira Avelino Lopes, Ernesto Brandão de Albuquerque Maranhão , Igor Martins de Brito, Vinicius Cerqueira de Barros Silveira, Suyane Del Vecchio Silva , Rosãngela Natalia Gomes Quintino de Holanda Cavalcante, Victória Souza Marques , Thomas Petrius Souza Marques, Juliana Silva Ribeiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
